论文部分内容阅读
目的:探讨血栓心脉宁胶囊对冠心病患者的疗效及对白细胞介素-6(IL-6),肿瘤坏死因子(TNF-α)及高敏C反应蛋白(hs-CRP)的影响。方法:65例冠心病患者随机分为治疗组33例和对照组32例。两组均采用常规治疗,治疗组加用血栓心脉宁胶囊,4粒/次,3次/d。疗程8周。观察IL-6,TNF-α,hs-CRP水平及心电图和心绞痛发作次数。结果:治疗组心绞痛总有效率90.9%,优于对照组的56.3%(P<0.01);治疗组心电图总有效率84.8%,优于对照组的56.3%(P<0.01);治疗后治疗组血清IL-6,TNF-α及hs-CRP水平均明显低于对照组(P<0.01)。结论:血栓心脉宁胶囊能减少患者心绞痛发作次数,改善患者心电图,并能降低患者IL-6,TNF-α,hs-CRP水平,其作用机制可能与抗炎症反应有关。
Objective: To investigate the therapeutic effect of Xueshun Xinmaining capsule on patients with coronary heart disease and its effect on interleukin-6, tumor necrosis factor (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) Methods: Sixty-five patients with coronary heart disease were randomly divided into treatment group (n = 33) and control group (n = 32). Both groups were treated with routine treatment, the treatment group with thrombosis Xinmaining Capsule, 4 capsules / time, 3 times / d. Treatment for 8 weeks. The levels of IL-6, TNF-α, hs-CRP and the frequency of electrocardiogram and angina pectoris were observed. Results: The total effective rate of angina pectoris in treatment group was 90.9%, which was superior to that in control group (56.3%, P <0.01). The total effective rate of electrocardiogram in treatment group was 84.8%, which was superior to that in control group (56.3%, P <0.01) Serum IL-6, TNF-α and hs-CRP levels were significantly lower than the control group (P <0.01). Conclusion: XHZD Capsule can reduce the number of angina pectoris, improve ECG and reduce the level of IL-6, TNF-α and hs-CRP in patients with CHF. Its mechanism may be related to anti-inflammation.